We came across a bullish thesis on Abbott Laboratories on r/ValueInvesting subreddit by anonymous_sheep1. In this article, we ...

Abbott Laboratories (NYSE:ABT) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. The company ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Abbott Laboratories' long-term plan is to make headway in this massive market by launching products adapted to different regions. Abbott isn't just a diabetes company, though.

Abbott Laboratories is a mammoth healthcare business whose market cap is around $180 billion. Even at a $30,000 investment, you would need the stock to be worth more than 33 times its valuation ...

Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than ...

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories increased its revenue from $20.2 billion in FY 2014 to $40.1 billion in FY 2023. That’s a compound annual growth rate of 7.9%. Very solid.